NCT06118905
Preserving Geriatric Muscle With an Osteoporosis Medication
Susan L. Greenspan·Phase 4·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Osteoporosis
- Drug/Device/Intervention
- Denosumab 60 MG/ML
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Susan L. Greenspan
- Funder
- University of Pittsburgh
Timeline & enrollment
- Phase
- Phase 4
- Start date
- Jan 01, 2024
- End date
- Apr 01, 2028
- Enrollment
- 248 participants
Primary outcome
Knee extension strength change
Summary
Our goal is to demonstrate efficacy of the novel agent Denosumab to improve or preserve
 muscle health, strength, mobility and function in frail older adults.
ICD-10 classifications
Osteoporosis, unspecifiedOther osteoporosisIdiopathic osteoporosisOsteoporosis in diseases classified elsewherePostmenopausal osteoporosis
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06118905
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06118905 through Pure Global AI's free database. This Phase 4 trial is sponsored by Susan L. Greenspan and is currently Not yet recruiting. The study focuses on Osteoporosis. Target enrollment is 248 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.